Our History

Founded in 2014, Longeveron is striving to address major, unmet market needs by providing stem cell products that effectively treat aging-related deficits in functional capacity, including Alzheimer’s disease, Frailty and Metabolic Syndrome, which impact millions of people in the U.S. Our novel and proprietary cell production technologies will make available products to healthcare providers for treatment of these currently incurable ailments and are based upon rigorous scientific and medical understanding of the cell therapeutic area.

Longeveron-grown Mesenchymal Stem Cells (LMSCs) have already undergone clinical testing with positive safety data results. Additional FDA approved clinical trials are underway as we strive to obtain FDA approval of our cell-based products and continue to demonstrate the safety and efficacy of the products as treatment for a range of conditions.